Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,480.00
0.00 (0.00%)
At close: Feb 6, 2026
52.29%
Market Cap910.43B +51.4%
Revenue (ttm)1.96B -87.6%
Net Income-21.96B
EPS-183.47
Shares Out96.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,842,402
Average Volume3,321,927
Open8,840.00
Previous Close9,480.00
Day's Range8,750.00 - 9,890.00
52-Week Range4,325.00 - 12,970.00
Beta0.93
RSI65.13
Earnings DateMar 18, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements